- Kindeva Drug Delivery has acquired Summit Biosciences Inc.
- The acquisition expands Kindeva’s capabilities across a wider range of complex drug-device combination products.
Kindeva Drug Delivery has announced the acquisition of Summit Biosciences Inc., an intranasal drug-delivery CDMO. This strategic move not only adds a new drug-delivery platform to Kindeva’s portfolio but also expands its capabilities across a wider range of complex drug-device combination products.
The acquisition is set to further enhance Kindeva’s position in the market, particularly in the areas of pulmonary, injectable, transdermal, and nasal drug delivery. This will allow the company to provide a more comprehensive service to its clients, catering to a broader range of pharmaceutical needs.
Kindeva CEO Milton Boyer, said: “Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting. Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva’s ambition to be a global leader in the drug-device combination products CDMO market, but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally.”
Departing Summit Chairman and CEO Richard D. Cohen added, “Joining Kindeva strengthens our ability to deliver best-in-class nasal product development and manufacturing. Under Kindeva’s leadership, our dedicated and talented workforce will further drive our founder’s vision of increasing the availability of nasal drug-delivery options.”
Overview of outsourcing trends 
